MyCural Therapeutics has recently been featured by Upsala Nya Tidning (UNT) as one of five notable Uppsala-based companies to watch—a recognition that highlights the region’s vibrant innovation ecosystem and our commitment to advancing cancer therapy.
Uppsala has long been known for its excellence in research, life sciences, and entrepreneurship. Being recognized within this context is a meaningful milestone for us at MyCural, as we continue to grow from our foundation in academic science toward becoming a clinical-stage biotechnology company.
Our work focuses on one of the most elusive yet critical targets in oncology: the MYC oncoprotein. Although MYC is believed to drive more than half of all human cancers, no therapies currently exist that directly target it. At MyCural, we are developing first-in-class drug candidates that have demonstrated highly promising effects in preclinical cancer models. Our team is now working diligently to refine these compounds and advance them toward clinical readiness within the coming years.
The support we have received from the Uppsala Innovation Centre (UIC) has played an important role in this journey. As our CEO, Alina Castell, notes:
“I can’t stop praising UIC and what they’ve meant for us – their support has been invaluable, especially for researchers like us bringing science into the business world.”
We would like to extend our sincere thanks to UNT for this recognition and to everyone who has contributed to our progress so far. As we look ahead, we remain focused on our mission: to develop innovative therapies that change the outlook for patients affected by some of the world’s most aggressive cancers.
Read the full article in Swedish here
